UBL5 Inhibitors
UBL5 inhibitors are a class of chemical compounds that specifically target the ubiquitin-like protein 5 (UBL5), a member of the ubiquitin-like (UBL) protein family. UBL5 plays a crucial role in various cellular processes, including the regulation of pre-mRNA splicing and mitochondrial function. By binding to UBL5, these inhibitors interfere with its normal interactions with other proteins, thereby modulating the pathways in which UBL5 is involved. Structurally, UBL5 inhibitors often contain functional groups that allow them to form strong interactions with the active or regulatory sites of UBL5. The design of these inhibitors typically involves detailed knowledge of the three-dimensional structure of UBL5 and the identification of key amino acid residues essential for its activity.
Research into UBL5 inhibitors focuses on understanding their binding mechanisms, optimizing their specificity, and minimizing off-target effects. Techniques such as X-ray crystallography and molecular docking simulations are employed to study the interactions between UBL5 and potential inhibitory compounds. These studies help in refining the chemical structures to enhance binding affinity and selectivity. Additionally, biochemical assays are used to evaluate the efficacy of UBL5 inhibitors in modulating UBL5 activity within cellular systems. By elucidating the precise mechanisms through which these inhibitors operate, researchers gain valuable insights into the fundamental biological processes governed by UBL5.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
17-DMAG | 467214-20-6 | sc-202005 | 1 mg | $205.00 | 8 | |
Alvespimycin, an Hsp90 inhibitor, can disrupt the proper folding and function of UBL5 as Hsp90 is involved in the folding of a subset of proteins. Inhibition of Hsp90 can lead to a destabilization of its client proteins, including UBL5, resulting in their degradation. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin binds to Hsp90, inhibiting its activity. Since Hsp90 is crucial for the maturation and stabilization of many proteins, its inhibition can cause a decrease in the functional stability of UBL5, as it may be a client protein of Hsp90. | ||||||
Radicicol | 12772-57-5 | sc-200620 sc-200620A | 1 mg 5 mg | $92.00 $333.00 | 13 | |
Radicicol operates similarly to geldanamycin by binding to Hsp90, potentially leading to the destabilization and degradation of UBL5 if it is an Hsp90 client protein, thereby inhibiting UBL5's function. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to bind to Hsp90 and can lead to the degradation of its client proteins. If UBL5 requires Hsp90 for stability, Withaferin A could result in the functional inhibition of UBL5. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an analog of geldanamycin that inhibits Hsp90, potentially causing the degradation of client proteins such as UBL5 if it relies on Hsp90 for conformational stability. | ||||||
Novobiocin | 303-81-1 | sc-362034 sc-362034A | 5 mg 25 mg | $128.00 $380.00 | ||
Novobiocin is an antibiotic that also inhibits Hsp90, potentially affecting the stability of UBL5 if it is among the substrates of Hsp90, thereby inhibiting UBL5's function. | ||||||
AT13387 | 912999-49-6 | sc-364415 sc-364415A | 10 mg 50 mg | $555.00 $1606.00 | ||
Onalespib, an Hsp90 inhibitor, could lead to the destabilization and potential degradation of UBL5 if it is a client protein of Hsp90, inhibiting its function. | ||||||
NVP-AUY922 | 747412-49-3 | sc-364551 sc-364551A sc-364551B sc-364551C sc-364551D sc-364551E | 5 mg 25 mg 100 mg 250 mg 1 g 5 g | $150.00 $263.00 $726.00 $1400.00 $2900.00 $11000.00 | 3 | |
Luminespib is an Hsp90 inhibitor that can destabilize Hsp90's client proteins. If UBL5 relies on Hsp90 for its stability, then its function would be inhibited by Luminespib. | ||||||
BIIB 021 | 848695-25-0 | sc-364434 sc-364434A | 5 mg 25 mg | $128.00 $650.00 | ||
BIIB021, an oral Hsp90 inhibitor, can potentially lead to the functional inhibition of UBL5 by destabilizing it if UBL5 is a client protein of Hsp90. | ||||||